COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study

COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study

Abstract Background Around 20% of venous thromboembolism (VTE) cases occur in patients with cancer. Current guidelines recommend low molecular weight heparin (LMWH) as the preferred anticoagulant for VTE treatment. However, some guidelines state that vitamin K antagonists (VKAs) and direct oral anti...

Full description

Bibliographic Details
Main Authors: Alexander T. Cohen, Anthony Maraveyas, Jan Beyer-Westendorf, Agnes Y. Y. Lee, Lorenzo G. Mantovani, Miriam Bach, on behalf of the COSIMO Investigators
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Thrombosis Journal
Subjects:
Active cancer
Health-related quality of life
Low molecular weight heparin
Patient preference
Recurrent venous thromboembolism
Rivaroxaban
Online Access:http://link.springer.com/article/10.1186/s12959-018-0176-2

Internet

http://link.springer.com/article/10.1186/s12959-018-0176-2

Similar Items